A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck

Condition:   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: Pembrolizumab;   Radiation: IMRT 60-66Gy
Sponsor:   Case Comprehensive Cancer Center
Not yet recruiting - verified February 2017

http://ift.tt/2meH689